Skip to content

Implementation Guided by aN Iterative, adapTivE Strategy - Induction of Labor

Protocol for a Sequential Multiple-Assignment Randomized Trial to Optimize an Adaptive Intervention to Promote Evidence-based Management of Induction of Labor: the IGNITE-IOL Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07547657
Acronym
IGNITE-IOL
Enrollment
64
Registered
2026-04-23
Start date
2026-04-01
Completion date
2028-09-01
Last updated
2026-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Birth; Induced

Keywords

Quality improvement, adaptive intervention, sequential multiple assignment randomized trial (SMART)

Brief summary

This trial is designed to investigate how best to support hospitals in improving induction management and clinical outcomes. The researchers will investigate an adaptive implementation strategy designed to support hospitals in increasing adherence to evidence-based practices for induction of labor.

Interventions

BEHAVIORALBASE

BASE (low-intensity, training and reporting, delivered virtually)

BEHAVIORALLEAD

LEAD (moderate-intensity, Quality Improvement (QI) leader-focused, delivered virtually)

BEHAVIORALTEAM

TEAM (very high-intensity, clinician-focused, delivered in-person)

Sponsors

University of Michigan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Masking description

Due to the need for investigators to participate in the delivery of the adaptive implementation intervention, neither investigators nor hospitals will be blinded to their assignment.

Intervention model description

This is a clustered, Sequential, Multiple Assignment Randomized Trial (SMART), with up to 64 hospital members of the Obstetrics Initiative (OBI) (see Figure 1). The unit of randomization will be the hospital. Time is measured in months since the onset of Stage 1, when all hospitals are offered BASE. The first randomization-to LEAD vs no LEAD with equal probability-occurs at the beginning of Month 6 (Stage 2). Subsequent randomizations-to TEAM vs no TEAM (Stage 3) with equal probability-occur at the beginning of Month 13, among non-Top Performer hospitals. This SMART will address how best to sequence different strategies across a population, informing the construction of an optimized, three-stage, 30-month adaptive implementation strategy for adherence to evidence-based IOL. This study is a clustered SMART because the sequential randomizations (e.g., to LEAD, to TEAM) are at the hospital level, while the outcome is at the level of providers nested within hospitals.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Maternity Clinicians (Individuals implementing QI initiatives on participating maternity units, all bedside clinicians on these units, and any other hospital employees identified by OBI champions as relevant to include, will be eligible to attend LEAD and TEAM activities.)

Exclusion criteria

* Individuals not working on these units are ineligible, which will exclude children under the age of 18 and retired, older adults.

Design outcomes

Primary

MeasureTime frameDescription
Provider-level adherence to evidence-based IOLUp to 30 monthsDefined as a percentage where the numerator = past month total number of evidence-based IOL techniques offered (regardless of whether they were completed, attempted unsuccessfully, or declined by the patient); and the denominator = past month total number of eligible opportunities to offer any evidence-based IOL technique. Data will be attributed at the individual provider level and analyzed at the provider level for the primary outcome. These data may also be aggregated at the hospital level-e.g., when examining whether % evidence-based IOL adherence at the hospital level is a moderator of the effects of LEAD and TEAM.

Secondary

MeasureTime frameDescription
Adherence to evidence-based induction technique 1 (dual-agent cervical ripening)Up to 30 monthsdefined as a percentage where the numerator = past month total number of offers of dual-agent cervical ripening (regardless of whether they were completed, attempted unsuccessfully, or declined by the patient); and the denominator = past month total number of eligible opportunities to offer dual-agent cervical ripening. Data will be attributed at the individual provider level and analyzed at the provider level for the secondary outcome.
Adherence to technique 2 (early amniotomy)Up to 30 monthsDefined as a percentage where the numerator = past month total number of offers of early amniotomy (regardless of whether they were completed, attempted unsuccessfully, or declined by the patient); and the denominator = past month total number of eligible opportunities to offer early amniotomy. Data will be attributed at the individual provider level and analyzed at the provider level for the secondary outcome.
Median time induction to birthUp to 30 monthsAverage time, in hours, between induction start time and time of birth
Percent delivery within 24 hoursUp to 30 MonthsProportion of patients undergoing induction who deliver within 24 hours of induction start
Median time induction to membrane ruptureUp to 30 MonthsAverage time, in hours, from induction start to time of rupture of membranes
Median time from rupture of membranes to birthUp to 30 MonthsAverage time, in hours, from time of rupture of membranes to time of birth

Countries

United States

Contacts

CONTACTCarey Simpson
simpsoca@umich.edu734-936-1644
PRINCIPAL_INVESTIGATORMichelle Moniz, MD, MSc

University of Michigan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 24, 2026